In a small trial at the University of Calgary, 82 percent of glioblastoma patients given high dose vitamin B3 alongside standard treatment were free of disease progression at six months, about 28 percent higher than figures from earlier studies.

Glioblastoma is the most aggressive form of brain cancer and remains incurable. One of its defences is suppressing the immune cells that would otherwise attack it. The researchers are testing whether controlled release niacin, a form of vitamin B3, can revive those suppressed immune cells, given alongside the usual chemotherapy and radiotherapy.

The trial had a stopping rule written in advance. If fewer than 20 percent more patients than in previous studies were progression free at six months, the work would halt. It passed that threshold.

This is an early stage trial with a small number of patients, and the researchers say larger studies are needed to establish whether the benefit is real and whether it is safe. They also caution that high doses of vitamins carry risks of their own.

Source: ScienceDaily, October 2026 https://www.sciencedaily.com/releases/2026/10/261001095423.htm.

#cancerresearch #glioblastoma #medicalresearch #clinicaltrial #fblifestyle

High-dose vitamin B3 is showing intriguing early promise as an addition to standard glioblastoma treatment, with 82% of patients in a small trial remaining progression-free after six months. Researchers believe niacin may help revive immune cells suppressed by the cancer, but larger studies are still needed to confirm the benefit and safety.